We are thrilled to announce a significant milestone for Celadon Pharmaceuticals Plc (AIM: CEL). Today, we proudly share that our private pain clinic, LVL Health, has received approval from the National Health Service (“NHS”) Research Ethics Committee to commence a chronic pain clinical trial for up to 5,000 patients.

The journey towards this approval has been marked by dedication and collaboration. Previously holding conditional approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), we embarked on an intensive Feasibility Study, culminating in positive outcomes for quality of life, pain, sleep, and a significant reduction in opioid usage.

Our approved Clinical Trial stands as a remarkable step towards making cannabis-based medicines more widely accessible in the UK. It aims to establish a comprehensive data set that will support doctors’ prescriptions, and in time, enable potential reimbursement by the NHS and insurance companies. In a groundbreaking move, General Practitioners can now prescribe this medicine to patients participating in the clinical trial alongside specialist doctors.

We believe this development will not only improve patient well-being but also revolutionise the UK market for cannabis-based medicines.